Johnson & Johnson is among the largest corporate donors, having contributed $966 million in cash and products toward nearly 600 programs in more than 50 countries, impacting tens of millions of lives worldwide. The Company contributed $131 million in cash to organizations in the United States and around the world for corporate and operating companies’ programs and projects. This included
$11 million allocated through our U.S. Matching Gifts program; Johnson & Johnson double-matched employee contributions in 2012 and made one-for-one contributions for donations from retirees, up to $10,000, for qualified nonprofit U.S. 501(c)(3) organizations.
Johnson & Johnson companies made $835 million in noncash contributions (product donations are reported at fair market value, which is consistent with the reporting methods of nonprofit organizations). Of these contributions, the Company donated $612 million of selected prescription products to patients without adequate financial resources in the U.S. through the Johnson & Johnson Patient Assistance Program. Over the past three years, our companies have provided more than 3 million units of medicine free of charge to nearly half a million U.S. patients. The balance of non-cash contributions went to private voluntary organizations that assist medically underserved people in developing countries and provide emergency disaster relief.
We manage our Contributions Program within guidelines approved by the Johnson & Johnson Executive Committee. Total giving of $966 million in 2012 showed a 37 percent increase over $706 million in 2011, an amount consistent with our continuing commitment to our philanthropic and patient assistance programs. Our Contributions budget is established well before the start of each fiscal year, so our giving as a percentage of year-end pretax income thus varies from year to year, as fluctuations in year-end pretax income become apparent. For 2012, our giving represented 7.0 percent of annual worldwide pretax income.
For more about our Corporate Contributions, visit here.